Irina Rivkind Koffler
Stock Analyst at Mizuho
(0.45)
# 4,062
Out of 4,947 analysts
31
Total ratings
25%
Success rate
-16.78%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Irina Rivkind Koffler
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EOLS Evolus | Assumes: Buy | $30 | $6.72 | +346.43% | 4 | Sep 5, 2019 | |
| DERM Journey Medical | Upgrades: Buy | $17 → $14 | $6.89 | +103.19% | 4 | Jun 6, 2019 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Neutral | $146 → $148 | $117.79 | +25.65% | 6 | May 8, 2019 | |
| PCRX Pacira BioSciences | Upgrades: Neutral | $29 → $38 | $24.75 | +53.54% | 4 | May 6, 2019 | |
| SUPN Supernus Pharmaceuticals | Maintains: Buy | $61 → $63 | $42.67 | +47.64% | 2 | Dec 17, 2018 | |
| TEVA Teva Pharmaceutical Industries | Maintains: Buy | $28 → $29 | $17.86 | +62.37% | 7 | Sep 17, 2018 | |
| IRWD Ironwood Pharmaceuticals | Upgrades: Buy | n/a | $1.05 | - | 4 | May 2, 2018 |
Evolus
Sep 5, 2019
Assumes: Buy
Price Target: $30
Current: $6.72
Upside: +346.43%
Journey Medical
Jun 6, 2019
Upgrades: Buy
Price Target: $17 → $14
Current: $6.89
Upside: +103.19%
Jazz Pharmaceuticals
May 8, 2019
Maintains: Neutral
Price Target: $146 → $148
Current: $117.79
Upside: +25.65%
Pacira BioSciences
May 6, 2019
Upgrades: Neutral
Price Target: $29 → $38
Current: $24.75
Upside: +53.54%
Supernus Pharmaceuticals
Dec 17, 2018
Maintains: Buy
Price Target: $61 → $63
Current: $42.67
Upside: +47.64%
Teva Pharmaceutical Industries
Sep 17, 2018
Maintains: Buy
Price Target: $28 → $29
Current: $17.86
Upside: +62.37%
Ironwood Pharmaceuticals
May 2, 2018
Upgrades: Buy
Price Target: n/a
Current: $1.05
Upside: -